A routine ski trip turned into an unexpected injury for Ali Burton. Watch how this one moment changed her perspective on pain and the path to recovery. Learn more: https://lnkd.in/ep5iqD5Y
Vertex Pharmaceuticals
Biotechnology Research
Boston, MA 515,487 followers
The Science of Possibility
About us
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and have made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continue to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our global HQ is in Boston, and we have research and development (R&D) sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards. Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/
- Website
-
https://www.vrtx.com/
External link for Vertex Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 1989
- Specialties
- cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus
Locations
Employees at Vertex Pharmaceuticals
Updates
-
We partnered with Scientific American to highlight the 24/7 burden of living with type 1 diabetes (T1D). Discover Anne and Andrew's powerful stories, exploring the 24-hour reality of living with T1D: https://lnkd.in/ejgiJhBN
-
We’re thrilled to celebrate Angie Angeles, who leads process chemistry at our San Diego site, for receiving the Women in Chemistry Trailblazer Award from the American Chemical Society San Diego Local Section! Angie plays an integral role in bridging medicinal chemistry scale-up with process chemistry to enable the progression of key programs into preclinical and clinical development. Her dedication and collaborative mindset are truly inspiring. Congratulations on this well-deserved recognition, Angie!
-
-
It’s great to be at ANESTHESIOLOGY 2025 in San Antonio to share insights about innovations in pain management and connect with the medical community. U.S. health care providers can find additional acute pain management resources and information at www.vrtxmedical.com/us
-
-
Exciting news! We’re featured on TIME’s 2025 Best Inventions list for innovation in pain management. For more than 20 years, our team has been committed to discovering nonopioid options to treat pain, and we are honored to be recognized for making a difference in the world through innovation.
-
-
Ali Burton’s journey with pain began with a skiing accident. Watch how she navigated the challenges that followed and found her voice on the path to recovery. Learn more: https://lnkd.in/ep5iqD5Y
-
We’re honored to be recognized as a Mass Save® 2025 Climate Leader, a testament to our ongoing commitment to sustainability and responsible business practices. We remain dedicated to improving energy efficiency and reducing greenhouse gas emissions at our newest Boston site through: • High-performance LED lighting and lab equipment • Heat pump technologies and demand control ventilation • On-site renewable energy from rooftop photovoltaics These technologies will eliminate an estimated 1,320 metric tons of CO2 annually. We’re committed to investing in innovative solutions that not only advance science but also protect our planet for future generations.
-
-
Congratulations to Angela Yen and William Eberley for making the BioSpace 40 Under 40 list! Angela’s pioneering work in AI, genomics and data science is shaping how we answer critical scientific questions and accelerate innovation. William’s expertise in bioprocess engineering and his dedication to advancing cell and genetic therapies are making an impact for patients worldwide. Let’s celebrate their achievements and the impact they make as leaders, mentors and trailblazers in biotech! Learn more about this year’s honorees: https://lnkd.in/eB_Xe-eS
-
-
What an incredible night at the PM360 Trailblazer Awards in New York City! We’re honored to be recognized for both our innovation and our leadership in the biopharma industry. This achievement is a testament to our unwavering commitment to patients and our fearless pursuit of advancing scientific research. We believe in the promise and potential of science to have a transformative impact — it starts with imagining what’s possible. Thank you to our talented team across the globe, whose dedication drives our progress forward.
-